Forensic drug screening in urine using liquid-chromatography-time-of-flight mass spectrometry: A qualitative/quantitative approach

Laura M. Huppertz[1], Karin Wendt[2], Michaela Schmidt[1], Ronja Peter[1], Franziska Ehrhardt[1], Carsten Baessmann[2], Volker Auwärter[1]

[1]*Institute of Forensic Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany*

[2]*Bruker Daltonik GmbH, Bremen, Germany*

UNIVERSITÄTS KLINIKUM FREIBURG

Institute of Forensic Medicine
Forensic Toxicology

Introduction

Full scan based screening methods using LC-QTOF-MS are a valuable tool for forensic analysis due to the possibility of qualitative/quantitative and retrospective data evaluation in a single run. In this study a previously developed LC-QTOF-MS screening workflow was validated for qualitative and quantitative analysis of drugs and drugs of abuse in human urine. To assess the methods' limitations regarding its applicability to urine screening in post-mortem toxicology, workplace drug testing, drug facilitated crime (DFC), and intoxication cases as well as to prove that cut-off values for sobriety and fitness-to-drive testing are met, a basic validation including limits of detection, limits of quantitation, linearity, accuracy, selectivity, and precision was carried out.

Methods

Sample Preparation

Ninety three substances of forensic relevance were spiked into ten different urine samples at the concentrations 1.0, 5.0, 10, and 50 ng/mL.



Samples were precipitated with cold acetonitrile after addition of seven isotope labeled compounds as internal standards (ISTD).

The dried residues were reconstituted and analyzed in duplicate on two LC-QTOF-MS systems in two different labs (Freiburg and Bremen).

Analytical Methods

Separation was performed on a Bruker Intensity Solo C18 column using a 14 min gradient elution. The MS (Bruker impact II) was operated in positive electrospray ionization mode generating a full scan and broad band CID spectra (bbCID) using collision energy spread.

HPLC:	Bruker Elute UHPLC
Column:	Bruker Intensity Solo 1.8 C18-2, 2.1*100 mm with pre-column
Mobile phase A:	H_2O/MeOH 99/1, 5 mM NH_4 formate / 0.01% HCOOH
Mobile phase B:	MeOH, 5 mM NH_4 formate / 0.01% HCOOH
Gradient:	multistep gradient 5 - 99.9% in 15 min (20 min cycle)
Flow rate:	flow gradient 0.2 - 0.48 mL/min,
Injection vol.:	2 µL
Column temp.:	40°C
MS:	Bruker impact II QTOF mass spectrometer
Ionization:	ESI(+), 2500 V
Scan range:	m/z 30 - 1000
	Full scan rapidly alternating TOF MS (4 eV) with bbCID (30 eV +/- 6 V) @ 2Hz

Compounds of Interest

For this evaluation 93 of the most common drugs, drugs of abuse, and their metabolites detected in routine case work at our institute were chosen.



Data Analysis

Data evaluation was performed with TASQ 1.4 software using the TargetScreener HR 3.0 accurate mass database containing mass spectrometric and chromatographic information of 2184 drugs, drugs of abuse, new psychoactive substances (NPS), metabolites, and pesticides.



Results

Limits of Detection (LOD) and Selectivity

LOD was set to the concentration at which a substance was detected in 95% of all measurements (n = 40, due to duplicate determination) according to the identification criteria on the right.

Identification at the lowest concentration (1.0 ng/mL) was achieved for 60% of the tested compounds.

Identification Criteria

- retention time ± 0.3 min
- signal to noise ratio > 3:1 for all ions
- $[M+nH]^{n+}$ and $[M+nH+1]^{n+}$ detected (MS)
- at least two qualifier ions with minimum one being a true fragment of the molecular ion (bbCID)

Only five compounds could not be detected in all samples at the investigated concentrations, probably due to matrix effects and/or low ionization yields.



Most substances with legal cut-offs according to German regulations for abstinence screening in fitness-to-drive assessment (CTU3 criteria), were detected well below the required cut-off concentrations.

Typical 'date rape drugs' showed LODs sufficient for detection of a recent uptake of these drugs.

Designer benzodiazepines and fentanyl derivatives were detected with high sensitivity.

Minimum LOQ requirements according to German CTU3 Criteria

Compounds	CTU3 LOQ	LC-QTOF LOQ
Amphetamines:		
Amphetamine	50 ng/mL	5.0 ng/mL
MDA	50 ng/mL	10 ng/mL
MDEA	50 ng/mL	10 ng/mL
MDMA	50 ng/mL	10 ng/mL
Methamphetamine	50 ng/mL	50 ng/mL
Cocaine:		
Benzoylecgonine	30 ng/mL	10 ng/mL
Cocaine	30 ng/mL	5.0 ng/mL
Opiates:		
Codeine	25 ng/mL	10 ng/mL
Dihydrocodeine	25 ng/mL	5.0 ng/mL
Morphine	25 ng/mL	5.0 ng/mL
Methadone:		
EDDP	50 ng/mL	1.0 ng/mL
Methadone	50 ng/mL	1.0 ng/mL
Benzodiazepines:		
Diazepam	50 ng/mL	1.0 ng/mL
Nordazepam	50 ng/mL	1.0 ng/mL
Oxazepam	50 ng/mL	1.0 ng/mL
Alprazolam	50 ng/mL	1.0 ng/mL
Hydroxyalprazolam	50 ng/mL	not investigated
Bromazepam	50 ng/mL	1.0 ng/mL
Flunitrazepam	50 ng/mL	1.0 ng/mL
7-Aminoflunitrazepam	50 ng/mL	50 ng/mL
Lorazepam	50 ng/mL	1.0 ng/mL
Cannabinoids:		
THC-COOH	10 ng/mL	> 50 ng/mL
Alcohol:		
Ethylglucuronide	100 ng/mL	not investigated

Quantitative Results

The linear dynamic ranges were four magnitudes or greater. LOQ was set to the lowest LOD. The precision ranged from 8 % to 30 %. The method showed good selectivity/specificity fulfilling the requirements, and overall accuracy met the criteria for bioanalytical method validation according to forensic guidelines.



Conclusion

The analytical possibilities and limitations of an LC-QTOF approach for screening urine samples were evaluated for 93 forensically relevant compounds with high prevalence in our everyday case work.

For a screening method, selectivity and LODs are the most important analytical parameters. Evaluated LODs were comparable with those of standard triple quadrupole (QqQ) methods for the majority of compounds investigated. Although, high end QqQ may reach lower LODs, considering the high number of analytes due to full scan analysis, LC-QTOF is a valuable tool for toxicological analysis and the presented LODs are sufficient for most analytical problems in everyday case work.

Given the high frequency of new psychoactive substances emerging on web-based drug markets and related fatalities, this is of particular interest to the forensic field due to the possibility of retrospective data evaluation. Extrapolating the here presented urine analysis results, application to blood and hair samples seems promising and will be evaluated in a subsequent study.

Acknowledgements

Parts of this work have been funded by the 'Deutsche Forschungsgemeinschaft' (DFG, German Research Foundation), **INST 380/92-1 FUGG**.

DFG

Contact

Laura M. Huppertz
Institute of Forensic Medicine
Medical Center - University of Freiburg
Albertstrasse 9, 79104 Freiburg,Germany
laura.huppertz@uniklinik-freiburg.de